Abstract: Automated reply messages such as “out-of-office” messages or “away” messages are messages that have been programmed for delivery on behalf of a user upon the receipt of another message intended for the user. An automated reply message typically includes relevant information regarding the user, such as supplemental contact information for the user, a duration of his or her unavailability, and an agent or other contact who may be reached on his or her behalf while he or she is unavailable. The information contained therein may be harvested and utilized for any means, including to protect the user against fraudulent attempted actions on his or her behalf that are not authorized by the user or an agent identified in the reply message.

Abstract: Automated reply messages such as “out-of-office” messages or “away” messages are messages that have been programmed for delivery on behalf of a user upon the receipt of another message intended for the user. An automated reply message typically includes relevant information regarding the user, such as supplemental contact information for the user, a duration of his or her unavailability, and an agent or other contact who may be reached on his or her behalf while he or she is unavailable. The information contained therein may be harvested and utilized for any means, including to protect the user against fraudulent attempted actions on his or her behalf that are not authorized by the user or an agent identified in the reply message.

Abstract: An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvant; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvant may be, for example, monophosphoryl lipid A, 3?-de-O-acetylated monophosphoryl lipid A, derivatives thereof, or any other adjuvant that enhances an individual's TH1 response to the antigen. Suitable amino acids include tyrosine, tryptophan, derivatives thereof, and the like. Methods for using the formulation are also provided; in a particularly preferred embodiment, the formulation is used as a vaccine.

Abstract: An apparatus and method of disconnecting or disabling an input/output terminal of an integrated circuit after packaging. Each input/output terminal of the integrated circuit includes a disabling device coupled thereto between the input/output terminal and the output driver of the respective input/output terminal. A DRAM module is disclosed having a plurality of partially good DRAM devices wherein the known bad input/output terminals are permanently disconnected using a disabling device, both the known good and known bad input/output terminals being coupled to conductive traces of a carrier substrate.

Abstract: An apparatus and method of disconnecting or disabling an input/output terminal of an integrated circuit after packaging. Each input/output terminal of the integrated circuit includes a disabling device coupled thereto between the input/output terminal and the output driver of the respective input/output terminal. A DRAM module is disclosed having a plurality of partially good DRAM devices wherein the known bad input/output terminals are permanently disconnected using a disabling device, both the known good and known bad input/output terminals being coupled to conductive traces of a carrier substrate.

Abstract: Provided is a pharmaceutical composition comprising tyrosine, an optionally modified allergen, and 3-DMPL, the is useful in the prevention and treatment of allergies.

Abstract: An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvant; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvant may be, for example, monophosphoryl lipid A, 3′-de-O-acetylated monophosphoryl lipid A, derivatives thereof, or any other adjuvant that enhances an individual's TH response to the antigen. Suitable amino acids include tyrosine, tryptophan, derivatives thereof, and the like. Methods for using the formulation are also provided; in a particularly preferred embodiment, the formulation is used as a vaccine.

Abstract: An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvants; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvants may be, for example, monophosphoryl lipid A, 3′-de-O-acetylated monophosphoryl lipid A, derivatives thereof, or any other adjuvants that enhances an individual's TH response to the antigen. Suitable amino acids include tyrosine, tryptophan, derivatives thereof, and the like. Methods for using the formulation are also provided; in a particularly preferred embodiment, the formulation is used as a vaccine.

Abstract: Pharmaceutical compositions are described for anti-allergy therapy comprising an allergen or allergen extract, polysarcosine having an average molecular weight in the range of 2,000 to 12,000 and a chemical linking group connecting a reactive site on the polysarcosine to an amino group on the allergen or allergen extract, the reactive site on the polysarcosine being a H(CH.sub.3)N--, the allergen extract being an extract from an allergen selected from pollens, weeds, house dust mites and venoms, and the chemical linking group having the formula --CO--B--CO where B is a hydrocarbon chain of 1-4 carbon atoms. The disclosure also describes the analogous conjugates.